Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Atrial Fibrillation
100%
Chronic Kidney Disease
100%
Cardiac Risk
100%
Cardiac Biomarkers
100%
Chronic Renal Insufficiency Cohort
100%
Incident Atrial Fibrillation
83%
Hazard Ratio
66%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
50%
High-sensitivity Troponin T
50%
High Concentration
33%
Galectin-3 (Gal-3)
33%
Soluble Suppression of Tumorigenicity 2 (sST2)
33%
Myocardial Stretch
33%
Categorical Data Analysis
33%
Growth Differentiation factor-15 (GDF-15)
33%
Inflammation
16%
Myocardial Fibrosis
16%
Hospitalization
16%
Myocardial Injury
16%
Large Cohort
16%
Dose-response Relationship
16%
High Burden
16%
Chronic Kidney Disease Patients
16%
Adjusted Hazard Ratio
16%
Adjusted Model
16%
Myocardial Cell Injury
16%
Atrial Fibrillation Risk
16%
Continuous Model
16%
Stretch Injury
16%
Medicine and Dentistry
Atrial Fibrillation
100%
Chronic Kidney Disease
100%
Biological Marker
100%
Cohort Analysis
100%
Hazard Ratio
41%
Amino Terminal Sequence
25%
Brain Natriuretic Peptide
25%
Troponin T
25%
Galectin 3
16%
Growth Differentiation Factor 15
16%
Prospective Study
8%
Fibrosis
8%
Cell Damage
8%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Chronic Kidney Failure
100%
Biological Marker
100%
Cohort Study
100%
Brain Natriuretic Peptide
25%
Troponin T
25%
Galectin 3
16%
Growth Differentiation Factor 15
16%
Inflammation
8%
Prospective Study
8%
Fibrosis
8%
Biochemistry, Genetics and Molecular Biology
Atrial Fibrillation
100%
Cohort Study
100%
N-Terminus
25%
Brain Natriuretic Peptide
25%
Troponin T
25%
Growth Differentiation Factor
16%
Galectin-3
16%
Prospective Study
8%
Cell Damage
8%